Vitality Biopharma Announces Proprietary THC Pharmaceutical with Greatly Decreased Psychoactivity

Vitality Biopharma, Inc a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has created a library of proprietary glycosides of THC (delta-9-tetrahydrocannabinol), the main psychoactive chemical found in cannabis or marijuana, which enable targeted delivery that reduces or eliminates psychoactivity when used in oral drug formulations.

Newly Developed Compounds Limit Psychoactivity & Cognitive Impairment

And May Be Especially Useful For Pediatric Applications

These compounds are being developed as pharmaceuticals that enable site-specific targeting of the THC in various tissues of the body, where it can exert therapeutic effects for treatment of pain and inflammation. In December, Vitality obtained DEA approval for its research and development facilities located in California, and it has now completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. The Company has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be reduced or eliminated.

This new drug opens up novel opportunities for treatment of pain and inflammation,” said Dr. Brandon Zipp, Director of R&D at Vitality. “We can now exploit the cannabinoid receptor system without systemic THC that compromises cognitive function.” Robert Brooke, CEO of Vitality, adds that, “It is THC without the high and could be a game changer, especially for treatment of indications like Crohn’s disease and for use in children.

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders.

For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

About Vitality Biopharma (OTCQB: VBIO)

This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies.

Notice Regarding Forward-Looking Statements

Address: 1901 Avenue of the Stars, 2nd FloorCity: Los Angeles

State: CAZip code: 90067

Country: USAPhone: (530) 231-7800Email: info@vitality.bio

Website: http://vitality.bioWeb Blog: http://vitality.bio/investors/news/

Twitter: hhttps://twitter.com/VitalityBioFacebook: https://www.facebook.com/VitalityBio

Linkedin.com: https://www.linkedin.com/company/vitality-biopharma?trk=company_logo

Contact USVitality Biopharma,

Inc.